[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","zekydasogv8d1vo7o3xpo7nfb","revision",2,"title","Indaptus Therapeutics 完成 2400 万美元私募融资","originalTitle","Indaptus Therapeutics, Inc. (0001857044) (Filer)","summary","Indaptus Therapeutics 完成 2400 万美元私募融资，发行 2033 万股东股。公司于 10 月 16 日完成交易，获资用于业务发展。股票代码 INDP 在纳斯达克上市。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-20T20:38:37.000Z","discoveredAt","2026-10-20T20:43:32.429Z","timelineAt","category","ai-products","tags",[80,81,82,83],"stockSymbols",[79],"score",43,"selected",false,"channel","news","story",{"_72":73,"_15":16},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fu9XlZuRwhDg",{"_72":73,"_15":16},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","22d1f33a-f3fe-4c52-abc1-a5e082746474",{"_72":73,"_15":16},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

Washington,\nDC 20549

FORM\n8-K

CURRENT\nREPORT

Pursuant\nto Section 13 or 15(d)

of\nthe Securities Exchange Act of 1934

Date\nof Report (Date of earliest event reported): October 16, 2026

INDAPTUS\nTHERAPEUTICS, INC.

(Exact\nname of registrant as specified in its charter)

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Delaware	001-40652	86-3158720
(State\n or other jurisdiction	(Commission	(IRS\n Employer
of\n incorporation)	File\n Number)	Identification\n No.)

\n \n \n \n \n \n \n \n \n \n \n \n \n

3\n Columbus Circle 15th Floor
New\n York, New York		10019
(Address\n of principal executive offices)		(Zip\n Code)

(646)\n427-2727

(Registrant’s\ntelephone number, including area code)

(Former\nname or former address, if changed since last report)

Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions (see General Instruction A.2. below):

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

☐	Written\n communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting\n material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement\n communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement\n communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities\nregistered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title\n of each class		Trading\n Symbol		Name\n of each exchange on which registered
Common\n Stock, $0.01 par value		INDP		Nasdaq\n Capital Market

Indicate\nby check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933\n(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging\ngrowth company ☐

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

As\npreviously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “Company”)\nwith the Securities and Exchange Commission (the “SEC”) on September 9, 2026, the Company entered into\na Stock Purchase Agreement, dated September 8, 2026 (the “Purchase Agreement”) with the purchasers party\nthereto (the “Purchasers”), pursuant to which the Company agreed to issue and sell an aggregate of 20,338,974\nshares (the “Shares”) of the Company’s common stock, par value $0.01 per share, in a private placement\n(the “Private Placement”), for aggregate gross proceeds of approximately $24.0 million, before deducting offering\nexpenses.

Subsequently,\nas reported in the Company’s Current Report on Form 8-K filed with the SEC on September 30, 2026, the Company and the Purchasers\nentered into notices and consents pursuant to which, among other things, the outside date applicable to each Purchaser under the Purchase\nAgreement was extended from September 29, 2026 to October 16, 2026.

Item\n8.01. Other Events.

On\nOctober 16, 2026, the Company completed the Private Placement, having received the full purchase price from each of the Purchasers in\naccordance with the terms of the Purchase Agreement, as amended. In connection with the closing of the Private Placement, the Company\nwill issue an aggregate of 20,338,974 Shares to the Purchasers.

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.

Date:\nOctober 20, 2026

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	INDAPTUS\n THERAPEUTICS, INC.

	By:	/s/\n Junyi Dai
	Name:	Junyi\n Dai
	Title:	Chief\n Executive Officer

","zhKind","complete","INDP","政策与监管","并购","融资","公司与财报","aihot","/items/zekydasogv8d1vo7o3xpo7nfb","https://www.sec.gov/Archives/edgar/data/1857044/000149315226047770/0001493152-26-047770-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792713600&sig=5c6d5f091d1967b7","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792713600&sig=86138d453cd8c096 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792713600&sig=e067c63cbf80f0de 96w","changelogVersion","2026-10-01T08:00"]